Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with CLL/SLL

Bookmark and Share
Published: 18 Dec 2019
Views: 438
Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia

Prof Constantine Tam speaks to ecancer at the 2019 ASH meeting in Orlando about the safety and efficacy of the novel BTK inhibitor zanubrutinib.

He reports that this agent has a more favourable safety profile compared to ibrutinib, due to its specificity.

Prof Tam describes the phase III SEQUOIA trial investigating zanubrutinib in chronic lymphocytic leukaemia (CLL) patients with a 17p deletion and reports that this group of patients had a high response rate of 92.7 percent.